Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials
Authors' conclusion
Rezafungin may enable shorter hospital and ICU LoS in IC/C compared with daily IV caspofungin, with accompanying savings in resource use.
Study context
- Population
- Patients with invasive candidiasis/candidemia (IC/C) in the ReSTORE and STRIVE trials, pooled modified intention to treat (mITT) population
- Participants
- 294 patients · 2 RCTs
- Comparison
- Once-weekly IV rezafungin vs daily IV caspofungin
- Rezafunginn = 139
- Caspofunginn = 155reference
- Outcome
- Hospital and ICU length of stay (LoS)
Methodological detailsexploratory, descriptive, generalised linear model adjusted for mechanical ventilation
- Exploratory
- Descriptive
- Generalised linear model adjusted for mechanical ventilation
Pooled result
As reported in the abstract
Total hospital LoS
Further pooled results
ICU LoS · adjusted for mechanical ventilation status
difference 4.1
| Outcome | Relative difference (95% CI) | |
|---|---|---|
| ICU LoSAdjusted for mechanical ventilation status | 24% (−11% to 72%) | |
| −50050100Difference (linear scale) |
- Physicians would have considered earlier discharge with weekly rezafungin
- 16% · 30
- Physicians would have considered earlier discharge with weekly rezafungin — Average days earlier
- 5-6
- Intensive care unit (ICU) length of stay (LoS): 126 (43%) had ICU admission
- Physicians would have considered earlier discharge with weekly rezafungin: 30/187; exploratory question, phase 3 trial
Original publication
Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials. Crit Care. Published 11 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →